Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-12-25
2007-12-25
Coleman, Brenda L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S250000
Reexamination Certificate
active
11092168
ABSTRACT:
Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure:including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein A is a ring moiety selected from:and wherein R1, R2, R3, X, Z, L1, Cycl1, L2and Cycl2are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.
REFERENCES:
patent: 0 837 063 (1998-04-01), None
patent: WO 96/09294 (1996-03-01), None
patent: WO 96/33981 (1996-10-01), None
patent: WO 01/21596 (2001-03-01), None
Bashyam Sridevi
Bearss David J.
Hurley Laurence H.
Mahadevan Daruka
Vankayalapati Hariprasad
Arizona Board of Regents on Behalf of The University of Arizona
Coleman Brenda L.
Montigen Pharmaceuticals, Inc.
Moore Susanna
Seed IP Law Group PLLC
LandOfFree
Substituted tricyclic compounds as protein kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted tricyclic compounds as protein kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted tricyclic compounds as protein kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3840491